Navigating Skyrizi Prior Authorization for Radiation Oncology Patients

Skyrizi's Role in Multidisciplinary Cancer Care Pathways

Skyrizi (risankizumab) is not a direct cancer therapy but is crucial for managing co-existing conditions like plaque psoriasis, psoriatic arthritis, or Crohn's disease in patients undergoing radiation therapy. This highlights the need for integrated prior authorization processes that acknowledge complex patient profiles, ensuring continuity of care for all active conditions while a patient receives radiation treatments such as IMRT, proton beam, or SBRT.

Clinical Guidelines and Medical Necessity for Risankizumab

While radiation oncology typically follows NCCN or ASCO guidelines for cancer treatment, Skyrizi's medical necessity is primarily established by guidelines from organizations like the American Academy of Dermatology (AAD) or the American Gastroenterological Association (AGA) for its approved indications. Prior authorization submissions must align with these specific guidelines, even when the patient is being managed by a radiation oncology department.

Essential Documentation for Skyrizi PA in Rad Onc Settings

• Prescribing specialist's clinical notes detailing diagnosis, disease severity, and prior treatment failures (e.g., from dermatology or gastroenterology).
• Relevant diagnostic test results supporting Skyrizi's indication (e.g., endoscopy reports for Crohn's, PASI scores for psoriasis).
• Attestation of medical necessity from the prescribing specialist, confirming the drug's ongoing role during radiation therapy.
• Documentation of any potential drug interactions or contraindications with radiation protocols, if applicable.
• Patient's comprehensive treatment plan, outlining both radiation therapy and concomitant systemic therapies.

Common Prior Authorization Denial Reasons Specific to This Intersection

Denials for Skyrizi prior authorization often stem from a lack of clear documentation linking its use to approved indications, especially when submitted by a department not directly managing the primary condition. Other reasons include insufficient evidence of prior therapy failures or a perceived lack of coordination between the oncology team and the prescribing specialist, leading payers to question medical necessity and adherence to ePA standards like X12 278.

Streamlining PA Workflows for Comorbid Conditions

Efficient prior authorization for drugs like Skyrizi in radiation oncology requires robust EMR integration and automated workflows. Klivira's platform facilitates seamless data exchange (e.g., via SMART on FHIR) and intelligent form completion, reducing manual effort and improving the accuracy of submissions for complex patient cases involving multiple specialists. This ensures compliance with payer requirements and supports timely patient access to care.